Will there be avaccine before the ? Incumbent US President Donald Trump certainly hopes so. But even if his long-shot prediction were to come true, the realities of producing, distributing and administering one or more COVID-19 vaccines mean it could still take months before most people in the US received one — and possibly even longer before life returns to some semblance of normal. That hasn’t stopped the Trump administration from ratcheting up expectations.
And vaccine manufacturers aren’t the only ones responding to pressure from the White House to hurry along the approval of a vaccine, either. Thethat some Chinese officials are taking Trump’s timeline seriously enough to rush approval of their own vaccines. That revelation comes on the heels of another investigation by the New York Times that details how China has been administering significant numbers of experimental coronavirus vaccines outside the typical testing process. Many worry that a similar disregard for safety protocols could lead to the premature approval of a vaccine in the US.
Currently, there are seven vaccine candidates being tested in the US, three of which are nearing the final stages needed for Food and Drug Administration approval. Considering Trump’s claim that vaccine development is being intentionally stifled.— the virus that causes COVID-19 — was only discovered less than a year ago, the progress is actually happening at a faster clip than ever before in the history of infectious disease (vaccines take, on average, about 10.7 years to develop), despite
Here, we survey the current landscape for a developing coronavirus vaccine. This article updates frequently and is intended to be a general overview and not a source of medical advice. If you’re seeking more information about coronavirus testing,.
Important COVID-19 vaccine news
COVID vaccine development is getting faster
Several acceleration efforts are currently underway, like the White House’s Operation Warp Speed, which is meant to cut through regulatory red tape to speed up vaccine development and be ready to distribute vaccines as soon as they receive FDA approval. So far, the US government has pledged over $10 billion to several vaccine manufacturers to secure a total of 800 million vaccine doses.
Vaccines typically take about 10 to 15 years to develop and approve, through four phases that include human trials. But with Operation Warp Speed, rather than submitting all sections of the application after all four phases are done, approved vaccine projects can submit data to the FDA bit by bit.
Meanwhile, the program is also financially backing efforts to start manufacturing doses while clinical trials are still ongoing. That means if and when those vaccines do get approved, there will already be a store of doses ready to distribute nationally. “I would hope that by the time we get well into the second half of 2021 that the companies will have delivered the hundreds of millions of doses they have promised,” Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, told Forbes in August.
Promising coronavirus vaccines from UK, US, China
Here’s a quick look at some of the frontrunners in the race to find a vaccine for COVID-19, including where the vaccines are being developed, where they are on testing them, and when scientists think they might be ready for widespread distribution, if known.
Oxford University/AstraZeneca (UK): AstraZeneca has paused testing of its vaccine, which it had begun on 100,000 human volunteers in at least three countries and was preparing to begin in the US. Lead researcher Dr. Sarah Gilbert had initially said they’re aiming for a fall 2020 release, which may now be delayed. However, UK Health Minister Matt Hancock has said such a pause is “not necessarily” a setback.
Moderna (US): An apparent scuffle with government regulators delayed large-scale human testing, but Moderna’s CEO has told Barron’s he still expects the company will know by Thanksgiving if the vaccine is safe and effective and should be able to distribute it in early 2021 if it is.
Pfizer (US): Although its four COVID-19 vaccine candidates are still in early-stage human trials, two of them have been fast-tracked by the FDA. Pfizer’s chief business officer told the US Congress the company may be ready to apply for FDA approval by October.
SinoVac (China): Currently testing its vaccine on about 10,000 human volunteers in China and about 9,000 in Brazil and is set to begin testing on about 1,900 test subjects in Indonesia soon. CEO of BioPharma, SinoVac’s Indonesian partner, has said he expects the vaccine to be ready by early 2021.
SinoPharm (China): Currently testing about 15,000 volunteers in the Middle East in a trial the state-owned company expects to last three to six months. Early results suggest the drug is safe and at least somewhat effective. SinoPharm recently built a second facility to manufacture the vaccine, doubling its capacity to about 200 million doses per year.
CanSino Biologics (China): Set to begin large-scale human trials this summer, CanSino’s vaccine has already been approved for the Chinese military. The vaccine is based on a modified common cold virus, which some experts warn could make it less effective than other vaccine efforts.
Will there be just one vaccine for everyone?
We probably won’t know until next year, but Fauci has suggested it might require several different vaccines made and distributed by different labs to bring an end to the pandemic, in a paper published May 11 in the journal Science. He also has said he foresees different vaccines being given to different patient populations. For example, one vaccine for elderly or other high-risk patients, another for healthy adults, another for children, etc.
What happens if we never find a coronavirus vaccine?
Coronaviruses are a large class of viruses and so far there are no vaccines for any of them. While there are promising early results, there’s no guarantee of a vaccine by 2021. Statistically, only about 6% of vaccine candidates ever make it through to market, according to a Reuters special report.
Early evidence suggests that the coronavirus doesn’t appear to mutate as quickly or often as the flu, and it’s thought that the virus has not yet mutated significantly enough to disrupt vaccine development — although our knowledge could change.
The longer we go without a vaccine, the more likely focus will shift toward treatments, such as the, which has reportedly shown promising results, and , a steroid that doctors say increases survival rates among the most serious cases. With effective therapeutic treatments, many viruses that used to be fatal are no longer death sentences. Patients with HIV, for example, can now expect to enjoy the same life expectancy as non-HIV-positive individuals, thanks to tremendous advances in treatment.
Eventually, the global population may reach the 60% to 70% rate required forto protect those who aren’t immune, which is, ultimately, the goal of a vaccine.